



Universiteit  
Leiden  
The Netherlands

## LC-MS/MS analysis of the central energy and carbon metabolites in biological samples following derivatization by dimethylaminophenacyl bromide

Willacey, C.C.W.; Naaktgeboren, M.; Moreno, E.L.; Wegrzyn, A.B.; Es, D. van der; Karu, N.; ... ; Hankemeier, T.

### Citation

Willacey, C. C. W., Naaktgeboren, M., Moreno, E. L., Wegrzyn, A. B., Es, D. van der, Karu, N., ... Hankemeier, T. (2019). LC-MS/MS analysis of the central energy and carbon metabolites in biological samples following derivatization by dimethylaminophenacyl bromide. *Journal Of Chromatography A*, 1608, 460413. doi:10.1016/j.chroma.2019.460413

Version: Publisher's Version

License: [Creative Commons CC BY-NC-ND 4.0 license](https://creativecommons.org/licenses/by-nc-nd/4.0/)

Downloaded from: <https://hdl.handle.net/1887/83264>

**Note:** To cite this publication please use the final published version (if applicable).



# LC–MS/MS analysis of the central energy and carbon metabolites in biological samples following derivatization by dimethylaminophenacyl bromide

Cornelius C.W. Willacey<sup>a,\*</sup>, Martijn Naaktgeboren<sup>a</sup>, Edinson Lucumi Moreno<sup>a</sup>, Agnieszka B. Wegrzyn<sup>a</sup>, Daan van der Es<sup>b</sup>, Naama Karu<sup>a</sup>, Ronan M.T. Fleming<sup>a</sup>, Amy C. Harms<sup>a</sup>, Thomas Hankemeier<sup>a,\*</sup>

<sup>a</sup> Analytical Biosciences and Metabolomics, Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands

<sup>b</sup> Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands

## ARTICLE INFO

### Article history:

Received 25 April 2019

Received in revised form 27 July 2019

Accepted 30 July 2019

Available online 31 July 2019

### Keywords:

Dimethylaminophenacyl bromide

Derivatization

Urine

LC–MS

N-Acetylated amino acids

TCA cycle

## ABSTRACT

Recent advances in metabolomics have enabled larger proportions of the human metabolome to be analyzed quantitatively. However, this usually requires the use of several chromatographic methods coupled to mass spectrometry to cover the wide range of polarity, acidity/basicity and concentration of metabolites. Chemical derivatization allows in principle a wide coverage in a single method, as it affects both the separation and the detection of metabolites: it increases retention, stabilizes the analytes and improves the sensitivity of the analytes. The majority of quantitative derivatization techniques for LC–MS in metabolomics react with amines, phenols and thiols; however, there are unfortunately very few methods that can target carboxylic acids at the same time, which contribute to a large proportion of the human metabolome. Here, we describe a derivatization technique which simultaneously labels carboxylic acids, thiols and amines using the reagent dimethylaminophenacyl bromide (DmPABr). We further improve the quantitation by employing isotope-coded derivatization (ICD), which uses internal standards derivatized with an isotopically-labelled reagent (DmPABr-D<sub>6</sub>). We demonstrate the ability to measure and quantify 64 central carbon and energy-related metabolites including amino acids, N-acetylated amino acids, metabolites from the TCA cycle and pyruvate metabolism, acylcarnitines and medium-/long-chain fatty acids. To demonstrate the applicability of the analytical approach, we analyzed urine and SUIT-2 cells utilizing a 15-minute single UPLC-MS/MS method in positive ionization mode. SUIT-2 cells exposed to rotenone showed definitive changes in 28 out of the 64 metabolites, including metabolites from all 7 classes mentioned. By realizing the full potential of DmPABr to derivatize and quantify amines and thiols in addition to carboxylic acids, we extended the coverage of the metabolome, producing a strong platform that can be further applied to a variety of biological studies.

© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Metabolomics, the younger sibling of genomics and proteomics, is a fast-evolving field which has established itself as a promising approach for understanding biological variations within a range of matrices in humans, animals, microbes and plants [1–8]. The quantitative profiling of metabolites in biological samples is challenging

due to the vast number of metabolites, variation in physicochemical properties and the wide range of concentrations in samples. All of these factors result in large differences in the recovery, sensitivity and matrix interferences of these metabolites when analyzed by various methods. Nevertheless, recent advances in mass spectrometry have given scientists the ability to further understand the human metabolome and focus more closely on selected pathway analysis. When we study metabolic pathways, we experience the complexity as they can comprise of many chemical conversions and are intertwined, making a targeted assay with coverage of over 50 relevant metabolites highly beneficial for researchers in metabolism.

\* Corresponding authors.

E-mail addresses: [C.c.w.willacey@lacdr.leidenuniv.nl](mailto:C.c.w.willacey@lacdr.leidenuniv.nl) (C.C.W. Willacey), [hankemeier@lacdr.leidenuniv.nl](mailto:hankemeier@lacdr.leidenuniv.nl) (T. Hankemeier).

Mass spectrometry (MS) has the ability to identify and quantify the metabolome with current methods reaching sensitivities down to picomolar concentrations, even without any prior separation [9]. However, in the majority of cases, chromatography prior to MS is used to better address the challenges introduced by ion suppression, separation of isomers and in-source fragmentation. The three most common separation techniques, LC, GC and CE, have provided robust methodologies to better cover the human metabolome. Each of these techniques has been applied to numerous types of metabolites, and each technique has tailored advantages for specific types of metabolites. For example, UPLC-MS (RP & HILIC) provides coverage for a large proportion of the metabolome with the advantages of high-throughput, sensitivity, reliability and robustness [10]. Still, in LC-MS, metabolites can suffer from limited sensitivity, or poor separation of particularly polar metabolites. Quantification of metabolites with electrospray ionization (ESI)-MS can suffer from ion suppression [11]. This interference can be corrected for by using coeluting isotopically-labelled internal standards, which are of limited availability and excessive costs.

Methods have been developed to combat these problems using advanced separation techniques and also chemical derivatization, which is the focus of this article. Chemical derivatization can be used to increase the separation resolution, sensitivity or to stabilize the metabolites, resulting in an increased metabolic coverage of MS-based metabolomics methods. For instance, benzoyl chloride is used to derivatize catecholamines and their metabolites to prevent oxidation and increase sensitivity in LC-MS [12]. In a recent review, Higashi and Ogawa [13] summarise the current techniques that are used for derivatization and conclude that isotope-coded derivatization (ICD) has the ability to enhance quantification in LC-MS(/MS). ICD is the process of labelling metabolites in a first sample with an unlabelled derivatization reagent and then using an isotopically labelled reagent to derivatize the same metabolite standards in a neat solution, i.e. pure solvent. This mixture, when added to the sample, can act as the corresponding internal standard (IS) for all analytes of interest. The benefit of this technique is the ability to introduce an isotopically labelled equivalent for all metabolites regardless of chemical structure complexity, which corrects for eventual ion suppression. Approaches such as ICD are important during derivatization workflows to compensate for possible matrix effects as the native matrix is altered due to derivatization. However, having an IS for each metabolite provides a tool to adjust for matrix interferences independent of the starting matrices. ICD can provide a cost-effective alternative when stable isotope IS are not available while still enabling improved trueness and precision. In this way, the derivatization reaction method is exploited in an additional manner next to modifying the separation and ionization of metabolites.

Several studies have utilized a range of reagents, some taking advantage of the ICD strategy to improve the quantitative performance [12,14,15]. Typical examples are benzoyl chloride [12,14] and dansyl chloride [15] which both label amines, thiols, phenols and some alcohols. Another reagent, dimethylaminophenacyl bromide (DmPABr), has been applied previously to label carboxylic acid groups [16]. There were inconsistent reports about the reactivity of DmPABr. Guo and Li [16] reported that DmPABr reacts only with carboxylic acids (i.e., not amines and thiols), and in a follow-up study Peng and Li acknowledged that it reacts also with nucleophiles at certain reaction conditions [17]. However, to conform with the aims of their method, liquid-liquid extraction (LLE) was applied to reduce the interference from amino acids and derivatives, by excluding them altogether. The need for a reliable method that combines labelling of the amine, thiol and carboxylic acid functional groups has been highlighted by previous papers that have

**Table 1**

List of the abbreviations for the metabolites analyzed in this method.

| Metabolite                    | Abbreviation | Metabolite                    | Abbreviation |
|-------------------------------|--------------|-------------------------------|--------------|
| Alanine                       | Ala          | <i>N</i> -acetylmethionine    | NA-Met       |
| Arginine                      | Arg          | <i>N</i> -acetylphenylalanine | NA-Phe       |
| Asparagine                    | Asn          | <i>N</i> -acetylproline       | NA-Pro       |
| Aspartic acid                 | Asp          | <i>N</i> -acetylserine        | NA-Ser       |
| Cysteine                      | Cys          | <i>N</i> -acetylthreonine     | NA-Thr       |
| Glutamine                     | Gln          | <i>N</i> -acetyltryptophan    | NA-Trp       |
| Glutamic acid                 | Glu          | <i>N</i> -acetyltyrosine      | NA-Tyr       |
| Glycine                       | Gly          | <i>N</i> -acetylvaline        | NA-Val       |
| Histidine                     | His          | Alpha-Ketoglutaric acid       | AKG          |
| Isoleucine                    | Ile          | Citric acids                  | CITS         |
| Leucine                       | Leu          | Fumaric acid                  | FUM          |
| Lysine                        | Lys          | Lactic acid                   | LAC          |
| Methionine                    | Met          | Malic acid                    | MAL          |
| Phenylalanine                 | Phe          | Oxaloacetic acid              | OXA          |
| Proline                       | Pro          | Pyruvic acid                  | PYR          |
| Serine                        | Ser          | Succinic acid                 | SUCC         |
| Threonine                     | Thr          | Acetylcarnitine               | AC           |
| Tryptophan                    | Trp          | Decanoylcarnitine             | DC           |
| Tyrosine                      | Tyr          | Hexanoylcarnitine             | HC           |
| Valine                        | Val          | Lauroylcarnitine              | LC           |
| <i>N</i> -acetylalanine       | NA-Ala       | Myristoylcarnitine            | MC           |
| <i>N</i> -acetylarginine      | NA-Arg       | Octanoylcarnitine             | OC           |
| <i>N</i> -acetylasparagine    | NA-Asn       | Palmitoylcarnitine            | PC           |
| <i>N</i> -acetylaspartic acid | NA-Asp       | Propionylcarnitine            | PPC          |
| <i>N</i> -acetylcysteine      | NA-Cys       | Stearoylcarnitine             | SC           |
| <i>N</i> -acetylglutamine     | NA-Gln       | Arachidonic acid              | AA           |
| <i>N</i> -acetylglutamic acid | NA-Glu       | Capric acid                   | DCA          |
| <i>N</i> -acetylglycine       | NA-Gly       | Caprylic acid                 | OCA          |
| <i>N</i> -acetylhistidine     | NA-His       | Dodecanoic acid               | DDA          |
| <i>N</i> -acetylisoleucine    | NA-Ile       | Oleic acid                    | OLA          |
| <i>N</i> -acetylleucine       | NA-Leu       | Undecanoic acid               | UDA          |
| <i>N</i> -acetyllysine        | NA-Lys       | Creatinine                    | CR           |


required two separate derivatization methods (DmPABr and dansyl chloride) to achieve the same coverage [18].

In the current paper, we expand the utilization of the reagent DmPABr to simultaneously derivatize metabolites with carboxylic acid, amine and thiol functional groups. We did not apply LLE, and analyzed amino acids, *N*-acetylated amino acids, carnitines, and organic acids using LC-MS in positive ionization mode. We have examined and optimised the reaction conditions to reliably and repeatably derivatize a range of metabolites and analyze them in a single, highly sensitive quantitative method. The reaction mechanism is identical to that of the reagent phenacyl bromide with primary amines [19], secondary amines [20,21], thiols [22,23] and carboxylic acid-containing metabolites (derivatization example shown in Fig. 1). First, we made adaptations to the method published by Guo and Li [16], Peng and Li [17], Stanislaus, Guo and Li [24] to improve the metabolite coverage to include a wide range of central carbon and energy-related metabolites. Then, we developed a targeted quantitative UPLC-MS/MS method to allow for the sensitive analysis of these metabolites in a single 10-minute analysis. The final applied method was successfully validated for linearity, precision, limits of detection (LOD) and quantification (LOQ). By applying this method to human urine and *in vitro* experiments using human pancreatic cancer cells (SUIT-2), we could confirm the broad applicability of this methodology and biological relevance for the scientific community.

## 2. Materials and methods

### 2.1. Chemicals

All of the chemicals were purchased from Sigma-Aldrich (St. Louis, USA) unless otherwise stated (abbreviations shown in Table 1). The LC-MS grade ACN was sourced from Actua-all Chemicals (Oss, The Netherlands) and de-ionized water was acquired



**Fig. 1.** Reaction scheme of DmpABr with cysteine showing the location of derivatization on the thiol (green) and carboxylic acid (blue), and twice on the primary amine (red). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).

using a Merck Milli-pore A10 purification system (Raleigh, USA). Stock solutions of 5 mg/mL Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val; 10 mM NA-Ala, NA-Arg, NA-Asn, NA-Asp, NA-Cys, NA-Gln, NA-Glu, NA-Gly, NA-His, NA-Leu, NA-Lys, NA-Met, NA-Phe, NA-Pro, NA-Ser, NA-Thr, NA-Trp, NA-Tyr, NA-Val; 1 mg/mL AKG, CIT, FUM, ICIT, LAC, MAL, OXA, PYR, SUCC were made in 1:1 DMSO/DMF and stored at  $-80^{\circ}\text{C}$ . Stock solutions of 2 mg/mL CR; 1 mg/mL AA, AC, BTA, DEA, DDA, EA, EIA, FOR, OLA, OCA, PA, PPA, SA, UDA in 100% ACN (v/v) and stored at  $-80^{\circ}\text{C}$ .

## 2.2. Derivatization reagent

The DmpABr reagent was purchased from BioConnect BV (Huisen, The Netherlands) and the internal standard DmpABr was synthesised following the published protocol by Guo and Li [16] using dimethyl sulphate- $\text{D}_6$  instead of dimethyl sulphate- $^{13}\text{C}_2$ . The structure of the reagent was confirmed using nuclear magnetic resonance (NMR). Also, with reference to the paper from Guo and Li [16], it is noted that the stability of the metabolites after reaction with DmpABr lasts for up to 6 months in a solution, and does not alter quantitative results [24]. The DmpABr reagent was stored in ACN at  $-80^{\circ}\text{C}$  to prevent the nucleophilic substitution reaction.

## 2.3. Method validation and biological application

### 2.3.1. Method optimization and validation

The following performance parameters were assessed on all 64 metabolites in triplicate. Method optimization started with the selection of an appropriate alkaline solution at a range of concentrations, comparing triethylamine (TEA at 0, 50, 100, 150, 250, 300, 500 and 750 mM) and triethanolamine (TEOA, at 0, 200, 400, 650, 700, 750, 800 and 1000 mM). The reaction time was assessed for the selected time points 0, 5, 15, 30, 45, 60, 90, 180 and 240 min using TEOA (750 mM) incubated for one hour at  $65^{\circ}\text{C}$ . Due to the ability of water to react with the reagent acting as a nucleophile the reaction was assessed in the presence of water at 0%, 20%, 40%, 60%, 80% and 100%. The final optimized method used 750 mM solution of TEOA for derivatization at  $65^{\circ}\text{C}$  for one hour in a shaking incubator. The method was characterised by a matrix-free 8-point calibration line, and by determining the carry-over by a solvent injection blank after injecting the highest calibration level (calibration point 7: Supplementary material Table S6). The calibration experiment was replicated ( $n=5$ ). Matrix effect (ME) is defined as "the direct or indirect alteration or interference in response due to the presence of unintended analytes (for analysis) or other interfering substances in the sample" [25]. The ME was calculated as the area of the internal standards in the neat solution against the area

of the internal standard in the presence of the matrix. The method was also assessed for linearity of the calibration line ( $n=5$ ) and LOD/LOQ. The LOD and LOQ were calculated using the following equations according to the ICH Q2R1 guidelines –  $\sigma$  being standard deviation of the signal in the blank injection:

$$\text{LOD} = (3.3 * \sigma) / \text{slope}$$

$$\text{LOQ} = (10 * \sigma) / \text{slope}$$

$$\text{ME}\% = \left( \frac{\text{Internal standard in neat solution}}{\text{internal standard in matrix}} \right) * 100$$

### 2.3.2. Urine validation samples

Urine from 10 healthy volunteers (aged 20–30) was collected and pooled and used for method optimization and validation. A volume of 10  $\mu\text{L}$  of urine was transferred to an Eppendorf safe-lock vial (0.5 mL). The urine was dried in a Labconco SpeedVac (MO, United States). The dried content was reconstituted in 10  $\mu\text{L}$  of DMSO/DMF to dissolve the remaining content. Then, 10  $\mu\text{L}$  of triethanolamine (750 mM) was added to the vial, followed by 10  $\mu\text{L}$  of DmpABr (82 mM). The sealed Eppendorf vial was placed into a shaking incubator for 60 min at  $65^{\circ}\text{C}$  to complete the derivatization. A total of 10  $\mu\text{L}$  of formic acid (30 mg/mL) was added to the vial to quench the reaction with an additional 30 min in the shaking incubator. Then, 5  $\mu\text{L}$  of DmpABr- $\text{D}_6$ -labelled metabolites were then added (concentrations in Supplementary material Table S6). Before vortexing, 45  $\mu\text{L}$  of ACN was also added to the vial. The content was then transferred to an HPLC vial for analysis. The trueness and precision of the method was generated by using a pooled sample of urine collected from healthy urine donors. Samples were analyzed in repeated experiments on 3 separate days in replicates each day ( $n=5$ ). Using this data, RSD calculations were performed to demonstrate the lack of variation in the derivatization conditions on separate days.

## 2.4. SUIT-2 oxidative stress analysis and validation

Human pancreatic cancer cells (SUIT-2) were cultured and placed into a 24-well plate, each containing  $1 * 10^6$  cells in 0.4 mL of culture media. The SUIT-2 cells were exposed to 1 nM, 10 nM and 100 nM of rotenone for 3, 8 and 24 h ( $n=3$ ). The cells were washed with PBS and transferred into an Eppendorf tube. The aliquots were centrifuged at 500 rpm to sediment the cells and the cell media was removed. To the cells, cooled methanol (80% v/v) was added to the cells before probe sonification, followed by centrifugation at



13,000 rpm to produce a protein precipitation; the supernatant was transferred to an Eppendorf safe-lock vial (1.5 mL) without disturbing the pellet. A volume equivalent to  $2.5 \times 10^5$  cell supernatant was taken to total dryness in a speed vacuum concentrator. The following were added to the vial and vortexed between additions: 10  $\mu$ L of DMSO/DMF (to first dissolve the dried content), 10  $\mu$ L of triethanolamine (750 mM) and 10  $\mu$ L of DmPABr (82 mM). The sealed Eppendorf vial was placed into a shaking incubator for 60 min at 65 °C to complete the derivatization. A volume of 10  $\mu$ L of formic acid (30 mg/mL) was added to the vial to quench the reaction with an additional 30 min in the incubation. Finally, 5  $\mu$ L of DmPABr- $D_6$ -labelled metabolites were diluted in 45  $\mu$ L of ACN and added to the vial. The content was then transferred to an HPLC vial for analysis.

### 2.5. LC-MS/MS analysis

Samples were analyzed by LC-MS using a Waters Acquity UPLC Class II (Milford, USA) coupled to an ABSciex QTrap 6500 series (Framingham, USA). The samples were run using scheduled multi-reaction monitoring (MRM) in positive mode with selected time windows. An injection of 1  $\mu$ L was made per sample to minimise detector saturation and maintain desirable peak shape. The analytical column used was a Waters AccQ-tag C18 column (2.1 mm  $\times$  100 mm, 1.8  $\mu$ m, 180 Å), maintained at 60 °C. Mobile phase solvent A was 0.1% v/v formic acid and 10 mM ammonium formate in water and mobile phase solvent B was 100% acetonitrile. Using the flow rate of 700  $\mu$ L/min, the gradient profile is as follows: initial, 0.2% B; 1.5 min, 20% B; 4 min, 50% B; 6 min, 90% B; 10 min, 99.8% B; 13 min, 99.8% B; 13.1 min, 0.2% B and 15 min, 0.2% B. The last 6 min allow for column washing and equilibration prior to the next injection. The following parameters were used for the AB Sciex QTrap 6500 analysis (MRM transitions shown in Table S2 of the Supplementary materials); electrospray ionization was used in positive mode at 4.5 kV. The gas temperature was 600 °C. Automated peak integration was performed using AB Sciex MultiQuant Workstation Quantitative Analysis for QTrap; all peaks were visually inspected to ensure adequate integration.

## 3. Results & discussion

### 3.1. Novel derivatization approach

DmPABr derivatization has been a successful method to support untargeted and targeted metabolomics platforms using ICD for carboxylic acid-containing metabolites. It was previously highlighted by Peng and Li [17] that DmPABr also reacts with the amine group of asparagine and labels it twice (once on the acid and once on the amine group), however the double labelled metabolite was reported to be the minor peak compared to the single derivatized form. As demonstrated in this paper, DmPABr can react with an amine group (once or twice) via a nucleophilic reaction in a quantitative manner, which is useful for LC-MS analysis. In comparison to another common reagent in LC-MS/MS, benzoyl chloride [12,14], the reagent DmPABr offers a more versatile and universal solution for derivatization. This reaction, however, is slower and forms a more stable bond, as DmPABr has the ability to react next to the amine group. It also reacts with carboxylic acids without forming an unstable anhydride as the bromine is attached to a methyl group rather than the acyl group. Therefore, we studied the ability of DmPABr to react with multiple functional groups such as the amine, carboxy and thiol groups and to use it for the metabolomics analysis of urine and cell samples.


### 3.2. Selection of metabolites and biological relevance

Utilizing the full capability of DmPABr allows us to extend from only derivatizing carboxylic acids to also targeting amines and thiols which broadens the applicability of the method significantly. To demonstrate this, we chose to measure central carbon and energy-related metabolites related to mitochondrial dysfunction as it requires the analysis of a broad range of chemically diverse metabolites. The key metabolites in aerobic respiration that are imperative for mammalian survival, such as  $\alpha$ -ketoglutaric acid, citrates, succinic acid, fumaric acid, malic acid and oxaloacetic acid, are frequently used references to determine changes in mitochondrial function and cellular health in metabolomics studies in urine, plasma and *in vitro* models [26]. *N*-Acetylation has been known to increase during mitochondrial dysfunction due to the elevation of acetyl-CoA. Therefore, *N*-acetylated amino acids reflect mitochondrial dysfunction and energy metabolism, and in addition are highly relevant in urine as they remove excess amino acids from the body [27,28]. Shifting of the energy balance from aerobic respiration to anaerobic respiration can also be noted by measurement of pyruvic acid and lactic acid which will both drastically increase [27]. An additional target group, acylcarnitines, was also selected, as it reflects energy processes, particularly following beta-oxidation and when fatty acids are transported into the mitochondria [27,29]. The last target group, fatty acids, is included to represent an alternative energy source by the mitochondria when sugars are inaccessible or depleted. Three common conditions that are often associated with mitochondrial dysfunction are Parkinson's disease [30], Leigh's syndrome [27] and diabetes [31]; all of which hold extensive interest within the scientific community.

### 3.3. Optimization of reaction conditions

We investigated and optimised the method to analyze amines, thiols and carboxylic acids to inform on central carbon and energy metabolism. We have found three key factors that affect the derivatization of the functional groups mentioned above: alkalinity of reaction solution, reaction time, and the presence of water during the reaction. Fig. 2A demonstrates that after 60 min the relative peak area did not increase significantly anymore, with high performance parameters (indicated in Table 2). This applied to all of the targeted functional groups: Ala (1° amine & carboxylic acids), NA-Asp (carboxylic acids), NA-Cys (thiol & carboxylic acid), PYR ( $\alpha$ -keto acid) and AC (carboxylic acid). This derivatization time was considered acceptable in terms of metabolic coverage. We have utilized similar inert base catalysts as in previous articles published for DmPABr that target the carboxylic acid function group, which utilized either 750 mM triethanolamine (TEOA) [16] or 200 mM triethylamine (TEA) [24]. Variations in response using these bases are depicted in Fig. 2B and C, leading to the selection of the appropriate conditions for derivatization of amine and thiol groups. Additional experiments indicated that 750 mM of TEOA was the optimum condition for consistent derivatization of metabolites in urine and cells (data not shown). TEOA (750 mM) also provided the most consistent derivatization indicated by identical values over the concentration range of 650–800 mM. TEOA was preferred because according to literature it causes less ion suppression in mass spectrometers, than TEA at the concentration tested [32].

Of the options for synthesized isotopically labelled DmPABr,  $D_6$  was used in place of  $^{13}C_2$  on the amine residue of DmPABr, as utilized for high-resolution MS by Guo and Li [16]. With this, we have been able to introduce a mass difference of 6 Da, which is preferable for low-resolution MS compared to the previous addition of 2 Da, and less costly. The mass difference of 2 Da with the internal standard DmPABr- $^{13}C_2$  provided cross-talk interference in



**Fig. 2.** DmPABr reaction optimization shown for 5 metabolites (Ala – Blue; NA-Asp – Red; NA-Cys – Green; PYR – Purple; AC – Orange;  $n=3$  per condition) representing the major classes selected in the method. (A) the effect of reaction time with 750 mM triethanolamine; (B) use of TEA as base; (C) use of TEOA as base; and (D) the reaction efficiency in the presence of water with 750 mM triethanolamine. The data is presented as peak area normalized to the highest peak area. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).

**Table 2**

Information relating to the carry-over, limit of detection (LOD), limit of quantification (LOQ) and linearity of an 8-point calibration line in aqueous solution. RSD was calculated using calibration point 4 (concentration shown in Supplementary Table S2).

| Analyte | LODs (nM) | LOQs (nM) | Fit ( $R^2$ ) | RSD(%) | Carryover (%) | Analyte | LODs (nM) | LOQs (nM) | Fit ( $R^2$ ) | RSD (%) | Carryover (%) |
|---------|-----------|-----------|---------------|--------|---------------|---------|-----------|-----------|---------------|---------|---------------|
| Ala     | 44.8      | 134       | 0.9938        | 7.7    | 0.01          | NA-Met  | 0.11      | 0.33      | 0.9867        | 4.4     | 0.003         |
| Arg     | 10.3      | 30.8      | 0.9944        | 6      | 0.004         | NA-Phe  | 0.27      | 0.82      | 0.9965        | 4.8     | 0.003         |
| Asn     | 4.01      | 12        | 0.9965        | 3.5    | 0.01          | NA-Pro  | 15.6      | 46.8      | 0.9969        | 12.5    | 0.05          |
| Asp     | 11.4      | 34        | 0.9915        | 9.9    | 0.02          | NA-Ser  | 5.55      | 16.6      | 0.9919        | 9.6     | 0.01          |
| Cys     | 49.5      | 148.6     | 0.9834        | 6      | 0.01          | NA-Thr  | 10.4      | 31.3      | 0.9987        | 3.7     | 0.01          |
| Gln     | 18.5      | 55.5      | 0.9913        | 12.3   | 0.02          | NA-Trp  | 2         | 6         | 0.9965        | 1.1     | 0.003         |
| Glu     | 43.5      | 130.5     | 0.9941        | 2.1    | 0.01          | NA-Tyr  | 0.12      | 0.37      | 0.9901        | 11.5    | 0.01          |
| Gly     | 932.4     | 2797      | 0.9952        | 1.8    | 0.32          | NA-Val  | 0.52      | 1.56      | 0.9932        | 13      | 0.002         |
| His     | 379.4     | 1138      | 0.9956        | 4.1    | 0.01          | AKG     | 29.7      | 89.1      | 0.9909        | 6.2     | 0.08          |
| Ile     | 9.28      | 27.9      | 0.9956        | 7.9    | 0.01          | CITS    | 1001      | 3003      | 0.9988        | 1.7     | 0.12          |
| Leu     | 11.3      | 33.9      | 0.9942        | 7.5    | 0.01          | FUM     | 69.5      | 208.5     | 0.9949        | 3.9     | 0.03          |
| Lys     | 142.8     | 428.3     | 0.9959        | 6.3    | 0.02          | LAC     | 2192      | 6578      | 0.9927        | 4       | 0.01          |
| Met     | 4.33      | 13        | 0.9903        | 0.6    | 0.01          | MAL     | 43.8      | 131.5     | 0.9979        | 1.6     | 0.01          |
| Phe     | 25.6      | 76.9      | 0.9997        | 10.2   | 0.02          | OXA     | 14        | 42        | 0.9950        | 1.7     | 0.02          |
| Pro     | 22.1      | 66.4      | 0.9870        | 3.6    | 0.003         | PYR     | 55.8      | 167.3     | 0.9926        | 2.4     | 0.004         |
| Ser     | 506       | 1518      | 0.9917        | 3.3    | 0.01          | SUCC    | 23.1      | 69.4      | 0.9997        | 3.8     | 0.02          |
| Thr     | 47.6      | 142.8     | 0.9950        | 2.9    | 0.01          | AC      | 0.36      | 1.09      | 0.9951        | 12.8    | 0.0001        |
| Trp     | 5.33      | 16        | 0.9978        | 9      | 0.02          | DC      | 0.3       | 0.91      | 0.9964        | 8       | 0.01          |
| Tyr     | 6.87      | 20.6      | 0.9966        | 7      | 0.02          | HC      | 0.61      | 1.82      | 0.9903        | 10.2    | 0.001         |
| Val     | 11.7      | 35.6      | 0.9939        | 10.5   | 0.01          | LC      | 0.9       | 2.7       | 0.9988        | 11.3    | 0.004         |
| NA-Ala  | 4.21      | 12.6      | 0.9941        | 4.3    | 0.002         | MC      | 0.5       | 1.5       | 0.9996        | 8.7     | 0.01          |
| NA-Arg  | 0.16      | 0.47      | 0.9989        | 9.1    | 0.001         | OC      | 1.32      | 3.98      | 0.9998        | 5.5     | 0.01          |
| NA-Asn  | 0.27      | 0.81      | 0.9882        | 11     | 0.02          | PC      | 0.91      | 2.72      | 0.9970        | 7.1     | 0.02          |
| NA-Asp  | 4.32      | 13        | 0.9942        | 3      | 0.002         | PPC     | 2.85      | 8.56      | 0.9985        | 8.5     | 0.0001        |
| NA-Cys  | 34.5      | 103.4     | 0.9975        | 4.6    | 0.06          | SC      | 0.25      | 0.75      | 0.9993        | 8.4     | 0.03          |
| NA-Gln  | 0.94      | 2.83      | 0.9979        | 6.7    | 0.001         | AA      | 4.45      | 13.4      | 0.9995        | 1       | 0.04          |
| NA-Glu  | 3.65      | 10.9      | 0.9979        | 1.5    | 0.02          | OCA     | 137       | 411       | 0.9992        | 4.2     | 0.02          |
| NA-Gly  | 3.32      | 9.97      | 0.9971        | 4.5    | 0.001         | DCA     | 104       | 314       | 0.9860        | 2.6     | 0.01          |
| NA-His  | 0.16      | 0.48      | 0.9917        | 3.7    | 0.001         | DDA     | 15.3      | 46        | 0.9912        | 4.5     | 0.01          |
| NA-Ile  | 27.7      | 83        | 0.9961        | 1.1    | 0.001         | OLA     | 185       | 555       | 0.9960        | 4.4     | 0.02          |
| NA-Leu  | 30.4      | 91.2      | 0.9946        | 1.5    | 0.001         | UDA     | 12.9      | 38.7      | 0.9985        | 4.2     | 0.008         |
| NA-Lys  | 72.6      | 217       | 0.9912        | 4.9    | 0.028         | CR      | 548.2     | 1644      | 0.9943        | 1.6     | 0.001         |


**Table 3**  
Method performance in urine of healthy men aged 18–30 to calculate concentration, intraday and interday precision calculated as %RSD. ND=Not Detected, N/A=Not Applicable.

| Analyte | Urine Concentration (μmol/mmol creatinine) | Intraday precision (%) | Interday precision (%) | Matrix effect (%) | Analyte         | Urine Concentration (μmol/mmol creatinine) | Intra-Day precision (%) | Inter-Day precision (%) | Matrix effect (%) |
|---------|--|------------------------|------------------------|-------------------|-----------------|--|-------------------------|-------------------------|-------------------|
| Ala     | 3.81                                       | 4.7                    | 5.1                    | 92.3              | NA-Met          | 0.03                                       | 2.3                     | 4                       | 37.7              |
| Arg     | 0.32                                       | 5.2                    | 9.5                    | 68.45             | NA-Phe          | 0.05                                       | 3.1                     | 4.2                     | 51.7              |
| Asn     | 1.11                                       | 4.9                    | 7                      | 74                | NA-Pro          | 1.31                                       | 29.3                    | 23.5                    | 31                |
| Asp     | 0.04                                       | 18.9                   | 16.5                   | 95                | NA-Ser          | 0.25                                       | 2.4                     | 4.1                     | 66.5              |
| Cys     | 11.5                                       | 12.9                   | 21                     | 91.2              | NA-Thr          | 1.7  | 3.2                     | 3.6                     | 53.9              |
| Gln     | 3.67                                       | 22.8                   | 18.5                   | 83.5              | NA-Trp          | 0.2  | 3.6                     | 3.7                     | 45.5              |
| Glu     | 0.12                                       | 5.5                    | 6.4                    | 81                | NA-Tyr          | 0.047                                      | 5                       | 9.8                     | 36.8              |
| Gly     | 136  | 1.4                    | 4.2                    | 67                | NA-Val          | 2.07                                       | 3.7                     | 13.2                    | 16.6              |
| His     | 76.3                                       | 5.2                    | 5.7                    | 42.7              | AKG             | 0.5  | 10.6                    | 12.8                    | 71.3              |
| Ile     | 0.23                                       | 6.7                    | 7.7                    | 80.3              | CITS            | 7.47                                       | 13.1                    | 11.5                    | 73.9              |
| Leu     | 0.52                                       | 6.4                    | 7                      | 85                | FUM             | 0.13                                       | 6.7                     | 7.7                     | 144.4             |
| Lys     | 1.22                                       | 23.1                   | 28                     | 42.2              | LAC             | 0.89                                       | 3.3                     | 8.9                     | 43.5              |
| Met     | 0.11                                       | 7.7                    | 11.9                   | 78.2              | MAL             | 0.13                                       | 7.1                     | 7.4                     | 42.8              |
| Phe     | 1.35                                       | 4.1                    | 9.2                    | 80.2              | OXA             | 0.3  | 3.9                     | 6.6                     | 57.2              |
| Pro     | 0.11                                       | 6.4                    | 6.7                    | 129.5             | PYR             | 0.17                                       | 11.5                    | 10.2                    | 50.3              |
| Ser     | 4.43                                       | 7.3                    | 15.5                   | 72.1              | SUCC            | 5.31                                       | 2.7                     | 3.4                     | 39.4              |
| Thr     | 1.21                                       | 6.3                    | 16.1                   | 70.2              | AC              | 1.93                                       | 4.2                     | 5                       | 83.38             |
| Trp     | 1.27                                       | 7.7                    | 7.6                    | 77.3              | DC              | 0.001                                      | 9.5                     | 7.8                     | 93.1              |
| Tyr     | 1.33                                       | 5.4                    | 6.8                    | 85                | HC              | ND   | N/A                     | N/A                     | 77.9              |
| Val     | 0.62                                       | 5                      | 7.3                    | 78.9              | LC              | ND   | N/A                     | N/A                     | 83.6              |
| NA-Ala  | 0.54                                       | 3.6                    | 6.7                    | 43.4              | MC              | ND   | N/A                     | N/A                     | 91.9              |
| NA-Arg  | 0.67                                       | 1.3                    | 1.5                    | 67.5              | OC              | 0.007                                      | 5.3                     | 5                       | 58.2              |
| NA-Asn  | 2.01                                       | 7.7                    | 7.4                    | 54.8              | PC              | ND   | N/A                     | N/A                     | 96.3              |
| NA-Asp  | 2.29                                       | 2.2                    | 5.4                    | 55.1              | PPC             | 0.07                                       | 2.2                     | 2.8                     | 88.7              |
| NA-Cys  | 1.45                                       | 4.1                    | 10.4                   | 27.4              | SC              | ND   | N/A                     | N/A                     | 95.4              |
| NA-Gln  | 1.26                                       | 5.5                    | 6.4                    | 34.7              | AA              | 0.02                                       | 9.4                     | 13.5                    | 103.6             |
| NA-Glu  | 0.67                                       | 3.6                    | 3                      | 62.3              | OCA             | ND   | N/A                     | N/A                     | 66.7              |
| NA-Gly  | 0.13                                       | 3.6                    | 7.1                    | 33.3              | DCA             | ND   | N/A                     | N/A                     | 90.7              |
| NA-His  | 1.28                                       | 3                      | 4.8                    | 63.9              | DDA             | 0.008                                      | 10.9                    | 24.1                    | 83.2              |
| NA-Ile  | 0.14                                       | 11.5                   | 10.3                   | 46.7              | OLA             | 0.006                                      | 11.2                    | 16.3                    | 95.8              |
| NA-Leu  | 0.13                                       | 4.9                    | 6.4                    | 47.6              | UDA             | 0.004                                      | 21.4                    | 39.1                    | 98.3              |
| NA-Lys  | 0.3  | 24                     | 22                     | 60                | CR <sup>a</sup> | N/A  | 4.5                     | 7.4                     | 38.1              |


<sup>a</sup> Creatinine was used for normalization.

**Table 4**  
Method performance in SUIT-2 cell to calculate concentration per mg and intra-day variability.

| Analyte | SUIT-2 Conc. (fmol/mg) | Intra-Day precision (%) | Matrix effect (%) | Analyte | SUIT-2 Conc. (fmol/mg) | Intra-Day precision (%) | Matrix effect (%) |
|---------|------------------------|-------------------------|-------------------|---------|------------------------|-------------------------|-------------------|
| Ala     | 408                    | 4.9                     | 121.1             | NA-Met  | 0.022                  | 1.8                     | 77.6              |
| Arg     | 243                    | 10.3                    | 75.8              | NA-Phe  | 0.063                  | 10                      | 78.3              |
| Asn     | 173                    | 6.7                     | 40.7              | NA-Pro  | 0.111                  | 9.6                     | 78.6              |
| Asp     | 56.8                   | 5.7                     | 75.1              | NA-Ser  | 13.1                   | 7.2                     | 73.8              |
| Cys     | 166                    | 30.8                    | 98.6              | NA-Thr  | 5.66                   | 5.7                     | 74.2              |
| Gln     | 2360                   | 10.1                    | 75.3              | NA-Trp  | 0.034                  | 10.8                    | 52.7              |
| Glu     | 474                    | 16.8                    | 83.3              | NA-Tyr  | 0.126                  | 6.5                     | 87                |
| Gly     | 2970                   | 3.4                     | 87.4              | NA-Val  | 0.034                  | 11.7                    | 86.3              |
| His     | 467                    | 3.7                     | 62.5              | AKG     | 7.75                   | 10                      | 93.7              |
| Ile     | 277                    | 8.7                     | 90.7              | CITS    | 214                    | 9.8                     | 97                |
| Leu     | 333                    | 9.7                     | 72.1              | FUM     | 245                    | 12.7                    | 131.8             |
| Lys     | 130                    | 28.5                    | 78.4              | LAC     | 846                    | 2.4                     | 72.5              |
| Met     | 127                    | 18.7                    | 87.9              | MAL     | 114                    | 3.8                     | 75.1              |
| Phe     | 309                    | 9                       | 70.2              | OXA     | 18.2                   | 13.6                    | 75.4              |
| Pro     | 206                    | 10.3                    | 114.5             | PYR     | 191                    | 1.4                     | 78.1              |
| Ser     | 270                    | 24.9                    | 105.1             | SUCC    | 249                    | 13.8                    | 60.6              |
| Thr     | 401                    | 31.1                    | 74.1              | AC      | 12.1                   | 13.8                    | 86.4              |
| Trp     | 59.7                   | 10.7                    | 97.8              | DC      | 0.006                  | 23.3                    | 109.5             |
| Tyr     | 284                    | 7.7                     | 66                | HC      | 0.033                  | 18.6                    | 81.5              |
| Val     | 307                    | 10.8                    | 76.4              | LC      | 0.01                   | 9.7                     | 85.6              |
| NA-Ala  | 3.05                   | 3.7                     | 82.1              | MC      | 0.099                  | 8                       | 94.1              |
| NA-Arg  | 0.699                  | 8.6                     | 74.2              | OC      | 0.011                  | 19.9                    | 68                |
| NA-Asn  | 159                    | 9.8                     | 64.8              | PC      | 0.195                  | 11.9                    | 98.4              |
| NA-Asp  | 56.6                   | 2                       | 76.7              | PPC     | 0.379                  | 7.4                     | 91.2              |
| NA-Cys  | 50.5                   | 12                      | 54.4              | SC      | 0.067                  | 9.4                     | 96.5              |
| NA-Gln  | 8.55                   | 8.6                     | 81.1              | AA      | 0.457                  | 19.5                    | 98.2              |
| NA-Glu  | 0.964                  | 2.1                     | 71                | OCA     | 2.57                   | 24.8                    | 67                |
| NA-Gly  | 3.75                   | 5.6                     | 53.3              | DCA     | 1.16                   | 27.3                    | 93.7              |
| NA-His  | 0.318                  | 19.6                    | 81.1              | DDA     | 1.64                   | 13                      | 83                |
| NA-Ile  | 0.126                  | 8                       | 56.1              | OLA     | 6.84                   | 14.7                    | 88.1              |
| NA-Leu  | 0.217                  | 14                      | 55                | UDA     | 0.669                  | 25.6                    | 88.9              |
| NA-Lys  | 0.045                  | 31.5                    | 84.2              | CR      | 305                    | 11.6                    | 81.7              |



**Fig. 3.** Demonstration of MS analysis of pyruvic acid: (A) in conventional negative ionization mode, holding a negative charge on the oxygen (green circle); (B) following DmPA labelling, producing a highly ionisable group (tertiary amine – red circle) and a higher retention group (blue circle). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).




**Fig. 4.** The common fragment formation of 180.0 Da & 134.1 Da: the product ion of the derivatization label and metabolite-specific product ions.

the triple-quadrupole MS with the metabolites labelled once, such as long-chain fatty acids and *N*-acetylated amino acids. However, this was not as detrimental to the metabolites labelled more than once (such as amino acids) as a mass difference gain of 18 Da was observed for metabolites such as Ala (labelled thrice) when using DmPABr-D<sub>6</sub>.

Other adaptations of the derivatization procedure were also evaluated, including the total elimination of the aqueous content prior to derivatization with DmPABr to improve reaction efficiency and decrease reaction variability. This was expected to be needed to create a quantitative method, unlike the previous published method that focused on identification. This variability and poor labelling efficiency may arise from the ability of water to act as a nucleophile under basic conditions (deprotonation).

It has previously been noted that as little as 5% water content during the derivatization reaction has the ability to reduce the labelling efficiency by hydrolysing DmPABr [23]. It was also reported that the presence of water competes with the metabolites to react with DmPABr as a nucleophile and thus hydrolysing the reagent [33]. We investigated whether a low percentage of water would interfere with the labelling of the amine group. Fig. 2D shows that the presence of 40% of water did not significantly change the derivatization efficiency. This may be explained by Stanislaus, Guo and Li [24], where the increase in DmPABr concentration from 20 mg/ml [16] to 40 mg/ml (excess reagent) resulted in 2-fold higher rate of the Sn2 reaction, ensuring completion of the reaction. The presence of water above 20% showed a decline in derivatization efficiency and in the presence of





**Fig. 5.** LC-MS/MS analysis of 64 metabolites after DmPABr derivatization in SUIT-2 cells. DmPA labelling pattern is also included (\* = labelled once; † = labelled twice; # = labelled thrice). (For interpretation of the references to colour in this figure, the reader is referred to the web version of this article).

100% water, the reaction is severely compromised. Therefore, we chose to conduct the reaction without the presence of water to avoid the complications due to possible hydrolysis of the reagent.

### 3.4. Targeted LC-MS/MS method


The aims of the chromatographic method were to combine high-throughput analysis with sensitive measurement of a wide range of chemical classes. After derivatization with DmPABr, polar compounds which are hardly retained in RP could be retained and separated, hence eliminating the need for HILIC separation. Moreover, derivatization with DmPABr allows sensitive and universal analysis in positive ionization mode, instead of in two ionization modes. By using DmPABr, we introduce the tertiary amine group (Fig. 3) that improves ionization hence enhances signals. Further improvement in intensity of measured metabolites can be gained by careful selection of MRMs. In Fig. 4A and B we illustrate that the metabolites that are labelled on the carboxylic acid show common and prominent fragments of 180.0 Da or 134.1 Da. These product fragments are ideal when measuring metabolites such as those involved in the TCA cycle as they lack nitrogen and are difficult to analyze in positive ionization mode without labelling. For metabolites which are labelled multiple times, such as amino acids, the fragments 180.0 Da and 134.1 Da are usually present (Fig. 4B) but are not selected as their signal is lower. Instead, a higher mass product ion giving a better signal is often seen. This results from derivatization twice on the amine group, and once on the acid moiety, yielding more sensitive fragments like 319.2 Da and 366.2 Da observed for arginine & alanine in Fig. 4C and D, respectively. Having a common fragmentation pattern reduces the specificity of metabolite species but with adequate chromatography, this issue can be negated. Additionally, a qualifier transition can also be set which will provide a unique fragmentation pattern to identify the specific metabolite but this will provide a lower sensitivity due to more MS/MS events. For the complete method, the labelling pat-

tern and the chosen MRM transitions are detailed in Supplementary Table S2.

To demonstrate the applicability of the method on biological samples, SUIT-2 cell extracts were subjected to derivatization and analysis, resulting in wide representation of various chemical classes (Fig. 5). The figure demonstrates that owing to strong retention of polar analytes (PYR, Gly) all 64 metabolites are detected in one run in positive ionization mode only within 8.4 min (latest elution, of arachidonic acid, AA). The derivatization leads to unique retention profile, such as the close elution between undecanoic acid (derivatized once) and leucine (derivatized three times), yet with baseline resolution between the isomers Ile and Leu. Another critical pair of isomers, CIT and ICIT present a common challenge in chromatography, and are not baseline resolved here (see Fig. 5), therefore are reported as total citrates (CITS). In contrast, good separation was observed for *N*-acetylated amino acids, many of which elute early. The first peak to elute was creatinine (Cr) which is often used to normalize and report metabolites in urine [34]. DmPABr can successfully derivatize creatinine, unlike the reagents utilized in commercially-available kits, that quantify non-derivatized creatinine (Biocrates AbsoluteIDQ<sup>®</sup> p180 Kit; Waters AccQ-Tag<sup>™</sup>).

### 3.5. Method performance in neat solutions

The methods performance incorporates the derivatization efficiency and the instrumental response. The method was validated for 64 metabolites that were deemed to be biologically relevant to assess the central energy and carbon metabolism. Using the ICD strategy, each metabolite had its corresponding DmPABr-D<sub>6</sub> internal standard to correct for ion suppression. This resulted in linear calibration lines for all metabolites in neat solutions (Table 2). All metabolites, including the amino acids which are derivatized by reacting 2–5 times with DmPABr showed a satisfactory linear calibration ( $R^2 > 0.99$ ) except for Cys ( $R^2 = 0.98$ ) and Pro ( $R^2 = 0.98$ ). The RSD for all metabolites in neat solution was recorded below 12.8% also shown in Table 2.



**Fig. 6.** Volcano plot of SUIT-2 cells exposed to 100 nM rotenone for 24 h vs control. All of the metabolites involved in the method show biological changes across all classes once treated with rotenone (amino acids – light purple; carnitines – blue; glycolysis – red; long-chain fatty acids – dark green; medium-chain fatty acid – light green; N-acetylated amino acids – dark purple; and TCA metabolites – orange). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).

N-Acetylated amino acids also showed good analytical performance similar to their free amino acid counterparts. Table 2 also shows that the carry-over of the method was negligible (<0.05%). Looking at limits of detection (which are affected by the derivatization process itself), N-acetylated amino acids have a very low LOD, as recorded for NA-Asp (4 nM), NA-Cys (34 nM) and NA-Phe (0.3 nM), which are sufficient for their analysis in urine and cells. N-Acetylated amino acids are used as the transport mechanism to excrete excess amino acids (particularly in the urine) that occur in relatively low concentrations when compared to free amino acids in urine [28,35]. We have circumvented the issues of limited dynamic range of the detector in order to allow good quantification of a wide concentration range of metabolites. As shown in Table 2, the LOD of Gly, His, Ser, CITS and LAC, were higher compared to the other metabolites in this method. This is due to intentional choice of less sensitive MRM channel, to reduce the signal and prevent detector saturation, counteracting the high physiological concentrations in urine or cells. Another intervention to prevent detector saturation took place, namely non-optimal ionization spray voltage throughout (4.5 kV vs. the optimal 5.5 kV). The application of this method to various matrices could benefit from tailoring the MS parameters as well as sample handling to improve the LOD.

### 3.6. Method performance in urine and cells

We applied the quantitative DmPABr method to urine and SUIT-2 cells (Tables 3 and 4). Table 3 shows the endogenous concentration of the metabolites measured in urine from healthy males, after normalization to creatinine (measured in the same method). A total of 57 compounds were detected and quantified in urine. The compounds that were not detected include some carnitines and medium chain fatty acids as they do not occur or occur in low concentrations in healthy urine. All of the amino acids and N-acetylated amino acids that have been studied fall within the expected concentrations curated in HMDB [3]. Urine was assessed

for intra-day and inter-day variability. Amino acids such as Ala, Ile, Trp had very low intra- and inter-day variability (all below 10%) and N-acetylated amino acids including NA-Asp, which is crucial for neurological studies, had an intra-day and inter-day variability of 2.2% and 5.4%, respectively. Creatinine had an intra-day and inter-day variability of 4.5% and 7.4%, respectively, which provides consistent normalization factor, if desired. Overall, the amino acids had a higher derivatization variability than other classes, which is probably due to the second step of derivatization on the 2° amine requiring more energy, compared to the single reaction with the carboxylic acid group.

The application of the method to cells was conducted by measuring untreated SUIT-2 cells. The cells were assessed for intra-day variability and not inter-day due to practical considerations (Table 4). All 64 metabolites were detected from the intra-cellular environment in cell lysate. This provided an excellent readout on the energy state of the cells using metabolites involved in the TCA cycle (i.e., CITS, FUM & SUCC) and glycolysis (PYR & LAC).

Matrix effect was calculated for both urine and cell samples. The matrix effect was significant during the early eluting peaks such as the N-acetylated amino acids in urine. However, the matrix interferences were not as high during the analysis of cells. The presence of a matrix effect shows the importance of using the ICD technique to provide an internal standard for all metabolites.

### 3.7. Method application in cells to reflect energy metabolism

Exposing cells to rotenone is a well-established method to induce mitochondrial dysfunction by blocking complex I of the electron transport chain. This allows us to simulate disorders such as Parkinson's disease and Leigh's syndrome. Application of the method to SUIT-2 cells exposed to 100 nM rotenone showed the most changes in the central metabolism when compared to 1 nM and 10 nM (data shown in Supplementary Figs. S4 & S5 for 8 and 3 h rotenone exposure). Out of the 64 metabolites, 28

showed significant changes including metabolites from all of the 7 classes (additional data shown in Supplementary Table S3). The top ten most distinguishing metabolites were: Asn ( $p=0.0001$ ); AKG ( $p=0.0001$ ); Pro ( $p=0.0004$ ); CITS ( $p=0.0004$ ); PYR ( $p=0.0004$ ); OXA ( $p=0.001$ ); FUM ( $p=0.002$ ); AC ( $p=0.002$ ); SUCC ( $p=0.002$ ) and MC ( $p=0.003$ ) as shown in Fig. 6. The two metabolites with the largest fold change, CITS and AKG, coincide with the shutdown of the TCA cycle by rotenone inhibition of complex I of the electron transport chain [36]. The same reduction was seen in SUCC and FUM but to a lesser extent. Interestingly, we also identified changes in the *N*-acetylated amino acids such as NA-Glu ( $p=0.01$ ), NA-Ala ( $p=0.003$ ). *N*-Acetylation of amino acids has been documented in mitochondrial dysfunction but has not been extensively studied due to difficulty with analysis [27,37,38]. The results obtained with our novel method demonstrate its potential in studying the role of central carbon and energy metabolism such as mitochondrial dysfunction and Parkinson's disease [39].

#### 4. Conclusions

The presented work expands the metabolite coverage of DmPABr by implementation of changes to the reaction conditions. Actually, the derivatization of several functional groups including carboxylic acids, primary amines, secondary amines and thiol groups was achieved in a consistent and robust way for the first time using DmPABr. This vastly improves the coverage of the method allowing for a higher proportion of the human metabolome to be targeted. We have demonstrated that using DmPABr derivatization to its full ability allows us to create a single RPLC-MS/MS analysis within 10 min acquisition time using only positive ionization mode. Since we used a targeted metabolomics method employing internal standards which were derivatized with stable isotope-labelled reagent, we can report each metabolite reliably with its absolute concentration. The great versatility of this approach was demonstrated by quantification of urine metabolites (normalized to DmPABr-derivatized creatinine). Applying the method to SUIT-2 cells exposed to rotenone showed significant changes in almost 50% of the metabolites covered in this method, including common TCA and glycolysis metabolites and not-so-commonly studied *N*-acetylated amino acids. Understanding and documenting these biological and biochemical changes in the brain could prove invaluable for future research into neurodegenerative diseases, and requires investigation with a precise and robust quantitative analytical approach. A computational approach towards the prediction of derivatization of metabolites, and the prediction of retention for new metabolites, will further support the method application to cover a wider range of metabolites in complex matrices.

#### Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

#### Acknowledgements

The author expresses thanks to: Jaco van Veldhoven for support during the synthesis of DmPABr-D<sub>6</sub>; Alisa L. Willacey for advice and guidance during the finalization of the study and Alida Kindt for statistical support. This project was supported by the SysMedPD project, which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no, 668738.

#### Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.chroma.2019.460413>.

#### References

- [1] L.M. Bayona, M. Videnova, Y.H. Choi, Increasing metabolic diversity in marine sponges extracts by controlling extraction parameters, *Mar. Drugs* 16 (2018).
- [2] N. Karu, L. Deng, M. Slae, A.C. Guo, T. Sajed, H. Huynh, E. Wine, D.S. Wishart, A review on human fecal metabolomics: methods, applications and the human fecal metabolome database, *Anal. Chim. Acta* 1030 (2018) 1–24.
- [3] D.S. Wishart, Y.D. Feunang, A. Marcu, A.C. Guo, K. Liang, R. Vazquez-Fresno, T. Sajed, D. Johnson, C. Li, N. Karu, Z. Sayeeda, E. Lo, N. Assempour, M. Berjanskii, S. Singhal, D. Arndt, Y. Liang, H. Badran, J. Grant, A. Serra-Cayuela, Y. Liu, R. Mandal, V. Neveu, A. Pon, C. Knox, M. Wilson, C. Manach, A. Scalbert, HMDB 4.0: the human metabolome database for 2018, *Nucleic Acids Res.* 46 (2018) D608–d617.
- [4] T. Li, E. Li, Y. Suo, Z. Xu, Y. Jia, J.G. Qin, L. Chen, Z. Gu, Energy metabolism and metabolomics response of Pacific white shrimp *Litopenaeus vannamei* to sulfide toxicity, *Aquat. Toxicol.* 183 (2017) 28–37.
- [5] N. Karu, R. Wilson, R. Hamede, M. Jones, G.M. Woods, E.F. Hilder, R.A. Shellie, Discovery of Biomarkers for Tasmanian Devil Cancer (DFTD) by metabolic profiling of serum, *J. Proteome Res.* 15 (2016) 3827–3840.
- [6] S.A. Goldansaz, A.C. Guo, T. Sajed, M.A. Steele, G.S. Plastow, D.S. Wishart, Livestock metabolomics and the livestock metabolome: a systematic review, *PLoS One* 12 (2017) e0177675.
- [7] L.W. Sumner, Z. Lei, B.J. Nikolau, K. Saito, Modern plant metabolomics: advanced natural product gene discoveries, improved technologies, and future prospects, *Nat. Prod. Rep.* 32 (2015) 212–229.
- [8] M. Ramirez-Gaona, A. Marcu, A. Pon, A.C. Guo, T. Sajed, N.A. Wishart, N. Karu, Y. Djombou Feunang, D. Arndt, D.S. Wishart, YMDB 2.0: a significantly expanded version of the yeast metabolome database, *Nucleic Acids Res.* 45 (2017) D440–d445.
- [9] V. Kantae, S. Ogino, M. Noga, A.C. Harms, R.M. van Dongen, G.L. Onderwater, A.M. van den Maagdenberg, G.M. Terwindt, M. van der Stelt, M.D. Ferrari, T. Hankemeier, Quantitative profiling of endocannabinoids and related *N*-acylethanolamines in human CSF using nano LC-MS/MS, *J. Lipid Res.* 58 (2017) 615–624.
- [10] B. Zhou, J.F. Xiao, L. Tuli, H.W. Resson, LC-MS-based metabolomics, *Mol. Biosyst.* 8 (2012) 470–481.
- [11] A.S. Lopes, E.C. Cruz, A. Sussulini, A. Klassen, Metabolomic strategies involving mass spectrometry combined with liquid and gas chromatography, *Adv. Exp. Med. Biol.* 965 (2017) 77–98.
- [12] P. Song, O.S. Mabrouk, N.D. Hershey, R.T. Kennedy, In vivo neurochemical monitoring using benzoyl chloride derivatization and liquid chromatography-mass spectrometry, *Anal. Chem.* 84 (2012) 412–419.
- [13] T. Higashi, S. Ogawa, Isotope-coded ESI-enhancing derivatization reagents for differential analysis, quantification and profiling of metabolites in biological samples by LC/MS: a review, *J. Pharm. Biomed. Anal.* 130 (2016) 181–193.
- [14] J.M. Wong, P.A. Malec, O.S. Mabrouk, J. Ro, M. Dus, R.T. Kennedy, Benzoyl chloride derivatization with liquid chromatography-mass spectrometry for targeted metabolomics of neurochemicals in biological samples, *J. Chromatogr. A* 1446 (2016) 78–90.
- [15] K. Guo, L. Li, Differential 12C-/13C-isotope dansylation labeling and fast liquid chromatography/mass spectrometry for absolute and relative quantification of the metabolome, *Anal. Chem.* 81 (2009) 3919–3932.
- [16] K. Guo, L. Li, High-performance isotope labeling for profiling carboxylic acid-containing metabolites in biofluids by mass spectrometry, *Anal. Chem.* 82 (2010) 8789–8793.
- [17] J. Peng, L. Li, Liquid-liquid extraction combined with differential isotope dimethylaminophenacyl labeling for improved metabolomic profiling of organic acids, *Anal. Chim. Acta* 803 (2013) 97–105.
- [18] Y. Sun, D. Chen, J. Liu, Y. Xu, X. Shi, X. Luo, Q. Pan, J. Yu, J. Yang, H. Cao, L. Li, L. Li, Metabolic profiling associated with autophagy of human placenta-derived mesenchymal stem cells by chemical isotope labeling LC-MS, *Exp. Cell Res.* 372 (2018) 52–60.
- [19] M. Egorov, B. Delpech, G. Aubert, T. Cresteil, M.C. Garcia-Alvarez, P. Collin, C. Marazano, A concise formation of *N*-substituted 3,4-diarylpyrroles – synthesis and cytotoxic activity, *Org. Biomol. Chem.* 12 (2014) 1518–1524.
- [20] Q. Hu, Z. Zhang, Y. Liu, T. Imamoto, W. Zhang, ZnCl<sub>2</sub>-promoted asymmetric hydrogenation of  $\beta$ -secondary-amino ketones catalyzed by a *P*-chiral Rh-bisphosphine complex, *Angew. Chem. Int. Ed.* 54 (2015) 2260–2264.
- [21] J. He, L. Shi, S. Liu, P. Jia, J. Wang, R. Hu, Ultrasound-mediated synthesis of *N,N*-bis(phenacyl)aniline under solvent-free conditions, *Monatsh. Chem. Mont.* 145 (2014) 213–216.
- [22] T.I. Yousef, E.S. Lewis, Group transfers. 1. Enolate structures contributing to the transition state for nucleophilic substitution on  $\alpha$ -substituted carbonyl compounds, *J. Am. Chem. Soc.* 109 (1987) 6137–6142.
- [23] H. Loghmani-Khouzani, M.R. Poorheravi, M.M.M. Sadeghi, L. Caggiano, R.F.W. Jackson,  $\alpha$ -Fluorination of  $\beta$ -ketosulfones by selectfluor™ F-TEDA-BF<sub>4</sub>, *Tetrahedron* 64 (2008) 7419–7425.

- [24] A. Stanislaus, K. Guo, L. Li, Development of an isotope labeling ultra-high performance liquid chromatography mass spectrometric method for quantification of acylglycines in human urine, *Anal. Chim. Acta* 750 (2012) 161–172.
- [25] V.P. Shah, K.K. Midha, J.W. Findlay, H.M. Hill, J.D. Hulse, I.J. McGilveray, G. McKay, K.J. Miller, R.N. Patnaik, M.L. Powell, A. Tonelli, C.T. Viswanathan, A. Yacobi, Bioanalytical method validation—a revisit with a decade of progress, *Pharm. Res.* 17 (2000) 1551–1557.
- [26] S. Hallan, M. Afkarian, L.R. Zelnick, B. Kestenbaum, S. Sharma, R. Saito, M. Darshi, G. Barding, D. Raftery, W. Ju, M. Kretzler, K. Sharma, I.H. de Boer, Metabolomics and gene expression analysis reveal down-regulation of the citric acid (TCA) cycle in non-diabetic CKD patients, *EBioMedicine* 26 (2017) 68–77.
- [27] J. Thompson Legault, L. Strittmatter, J. Tardif, R. Sharma, V. Tremblay-Vaillancourt, C. Aubut, G. Boucher, C.B. Clish, D. Cyr, C. Daneault, P.J. Waters, L. Vachon, C. Morin, C. Laprise, J.D. Rioux, V.K. Mootha, C. Des Rosiers, A metabolic signature of mitochondrial dysfunction revealed through a monogenic form of Leigh syndrome, *Cell Rep.* 13 (2015) 981–989.
- [28] A. Mardinoglu, S. Shoaie, M. Bergentall, P. Ghaffari, C. Zhang, E. Larsson, F. Backhed, J. Nielsen, The gut microbiota modulates host amino acid and glutathione metabolism in mice, *Mol. Syst. Biol.* 11 (2015) 834.
- [29] J.C. Schoeman, J. Hou, A.C. Harms, R.J. Vreeken, R. Berger, T. Hankemeier, A. Boonstra, Metabolic characterization of the natural progression of chronic hepatitis B, *Genome Med.* 8 (2016) 64.
- [30] I. Celardo, L.M. Martins, S. Gandhi, Unravelling mitochondrial pathways to Parkinson's disease, *Br. J. Pharmacol.* 171 (2014) 1943–1957.
- [31] S.H. Adams, Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state, *Adv. Nutr.* 2 (2011) 445–456.
- [32] Z. Wu, W. Gao, M.A. Phelps, D. Wu, D.D. Miller, J.T. Dalton, Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry, *Anal. Chem.* 76 (2004) 839–847.
- [33] M. Nallu, M. Subramanian, N. Vembu, A. Akber Hussain, Effect of binary aqueous-organic solvents on the reaction of phenacyl bromide with nitrobenzoic acid(s) in the presence of triethylamine, *Int. J. Chem. Kinet.* 36 (2004) 401–409.
- [34] R.B. Knobel, J.M. Smith, Laboratory blood tests useful in monitoring renal function in neonates, *Neonatal Netw.* 33 (2014) 35–40.
- [35] T. Kawase, M. Nagasawa, H. Ikeda, S. Yasuo, Y. Koga, M. Furuse, Gut microbiota of mice putatively modifies amino acid metabolism in the host brain, *Br. J. Nutr.* 117 (2017) 775–783.
- [36] M. Garmier, A.J. Carroll, E. Delannoy, C. Vallet, D.A. Day, I.D. Small, A.H. Millar, Complex I dysfunction redirects cellular and mitochondrial metabolism in *Arabidopsis*, *Plant Physiol.* 148 (2008) 1324–1341.
- [37] M. de Tommaso, E. Ceci, C. Pica, M. Trojano, M. Delussi, G. Franco, P. Livrea, M. Ruggieri, Serum levels of *N*-acetyl-aspartate in migraine and tension-type headache, *J. Headache Pain* 13 (2012) 389–394.
- [38] E. Gerlo, R. Van Coster, W. Lissens, G. Winckelmans, L. De Meirleir, R. Wevers, Gas chromatographic-mass spectrometric analysis of *N*-acetylated amino acids: the first case of aminoacylase I deficiency, *Anal. Chim. Acta* 571 (2006) 191–199.
- [39] P.A. Lewitt, J. Li, M. Lu, T.G. Beach, C.H. Adler, L. Guo, 3-Hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis, *Mov. Disord.* 28 (2013) 1653–1660.